For only the fourth time since World War II, the U.S. midterm election flipped control of both the House and the Senate. (The ...
Colorectal cancer (CRC) remains difficult to treat, particularly after resistance to targeted therapies and immunotherapy ...
At last week’s World Congress on Pain, Kinoxis Therapeutics Pty and the University of Sydney reported data regarding their ...
A pair of popular modalities stands at the back-end-loaded, potential $7 billion-plus deal inked by Boehringer Ingelheim GmbH and Sino Biopharmaceutical Ltd.: antibody-drug conjugates (ADCs) and ...
The publication this spring in The Lancet Respiratory Medicine of new data with Amgen Inc. and Astrazeneca plc’s Tezspire (tezepelumab) fed hopes in severe asthma, where a handful of developers are ...
Researchers are taking new steps to improve CAR T-cell therapies by better understanding their behavior and engineering them to overcome some of their limitations, from treatment failure and T-cell ...
Prostate-specific membrane antigen (PSMA) is overexpressed in primary and metastatic prostate cancer, including metastatic lesions in lymph nodes and bone, compared with normal prostate tissues. ADC ...
Highslab Therapeutics Inc. recently provided details on HL-7037, a cyclic peptide designed to selectively target glypican-3 ...
Blackstone Life Sciences entered into a $455 million deal with Boston Scientific Corp. to co-fund the development of Vitalyst ...
At Bioplus Interphex Korea 2026 in Seoul, panelists noted that “transformative” technological architecture, including large ...
Fresenius SE & Co. KGaA has secured exclusive options to develop up to 37 biosimilars with Wuxi Biologics Co. Ltd. in a ...
A person’s DNA sequence is largely the same across cells, but the effects of genetic variation can differ sharply. Three ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results